Literature DB >> 8723462

Interaction between ganciclovir and foscarnet as inhibitors of duck hepatitis B virus replication in vitro.

G Civitico1, T Shaw, S Locarnini.   

Abstract

Safe and effective treatments for chronic hepatitis B virus (HBV) infection have yet to be developed. Both ganciclovir (9-[1,3-dihydroxy-2-propoxymethyl]guanine) and foscarnet (trisodium phosphonoformate hexahydrate) are potent inhibitors of hepadnavirus replication when used individually in vitro and in vivo. However, the clinical usefulness of each drug is reduced by dose-limiting toxicity, especially during long-term monotherapy. Here we demonstrate additive inhibition of duck HBV DNA replication in cultures of primary duck hepatocytes congenitally infected with duck HBV by combinations of ganciclovir and foscarnet at low, clinically achievable concentrations. These results suggest that the effects of ganciclovir and foscarnet against HBV may be additive in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8723462      PMCID: PMC163287          DOI: 10.1128/AAC.40.5.1180

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  38 in total

Review 1.  A three-dimensional model to analyze drug-drug interactions.

Authors:  M N Prichard; C Shipman
Journal:  Antiviral Res       Date:  1990 Oct-Nov       Impact factor: 5.970

2.  Inhibition of HBV DNA replication by ganciclovir in patients with AIDS.

Authors:  S Locarnini; K Guo; R Lucas; I Gust
Journal:  Lancet       Date:  1989-11-18       Impact factor: 79.321

3.  Evaluation of synergism or antagonism for the combined action of antiviral agents.

Authors:  J Sühnel
Journal:  Antiviral Res       Date:  1990-01       Impact factor: 5.970

4.  Comparative activities of several nucleoside analogs against duck hepatitis B virus in vitro.

Authors:  T Yokota; K Konno; E Chonan; S Mochizuki; K Kojima; S Shigeta; E de Clercq
Journal:  Antimicrob Agents Chemother       Date:  1990-07       Impact factor: 5.191

5.  Antiviral strategies in chronic hepatitis B virus infection: I. Establishment of an in vitro system using the duck hepatitis B virus model.

Authors:  N Bishop; G Civitico; Y Y Wang; K J Guo; C Birch; I Gust; S Locarnini
Journal:  J Med Virol       Date:  1990-06       Impact factor: 2.327

6.  Antiviral strategies in chronic hepatitis B virus infection: II. Inhibition of duck hepatitis B virus in vitro using conventional antiviral agents and supercoiled-DNA active compounds.

Authors:  G Civitico; Y Y Wang; C Luscombe; N Bishop; G Tachedjian; I Gust; S Locarnini
Journal:  J Med Virol       Date:  1990-06       Impact factor: 2.327

7.  Foscarnet therapy in chronic hepatitis B virus E antigen carriers.

Authors:  V G Bain; H M Daniels; A Chanas; G J Alexander; R Williams
Journal:  J Med Virol       Date:  1989-10       Impact factor: 2.327

8.  Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro.

Authors:  J F Manischewitz; G V Quinnan; H C Lane; A E Wittek
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

9.  Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo.

Authors:  V R Freitas; E B Fraser-Smith; T R Matthews
Journal:  Antiviral Res       Date:  1989-11       Impact factor: 5.970

10.  Inhibition of RNA- and DNA-dependent duck hepatitis B virus DNA polymerase activity by nucleoside and pyrophosphate analogs.

Authors:  B Löfgren; E Nordenfelt; B Oberg
Journal:  Antiviral Res       Date:  1989-12       Impact factor: 5.970

View more
  4 in total

1.  The intracellular activation of lamivudine (3TC) and determination of 2'-deoxycytidine-5'-triphosphate (dCTP) pools in the presence and absence of various drugs in HepG2 cells.

Authors:  S Kewn; P G Hoggard; S D Sales; M A Johnson; D J Back
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

Review 2.  Combination chemotherapy for hepatitis B virus: the path forward?

Authors:  T Shaw; S Locarnini
Journal:  Drugs       Date:  2000-09       Impact factor: 9.546

3.  In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir.

Authors:  M Seifer; R K Hamatake; R J Colonno; D N Standring
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.938

4.  The Inaugural Australian Centre for Hepatitis Virology Public Panel Discussion on Viral Hepatitis Research-Lessons in Scientific Community Outreach.

Authors:  Thomas Tu; Chaturaka Rodrigo; Simone I Strasser; D Scott Bowden; Jennifer H MacLachlan; Heidi E Drummer
Journal:  Viruses       Date:  2021-09-15       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.